Long-term evaluation of a fully magnetically levitated circulatory support device for advanced heart failure-two-year results from the HeartMate 3 CE Mark Study.


Journal

European journal of heart failure
ISSN: 1879-0844
Titre abrégé: Eur J Heart Fail
Pays: England
ID NLM: 100887595

Informations de publication

Date de publication:
01 2019
Historique:
received: 05 12 2017
revised: 11 06 2018
accepted: 26 06 2018
pubmed: 28 7 2018
medline: 22 5 2019
entrez: 28 7 2018
Statut: ppublish

Résumé

This study aimed to assess safety and outcomes of patients, 2 years after implantation with the HeartMate 3 Left Ventricular Assist System. This study included 50 adults with New York Heart Association (NYHA) class IIIB or IV symptoms or American College of Cardiology/American Heart Association stage D heart failure with an ejection fraction ≤25% and a cardiac index ≤2.2 L/min/m Two years post-HeartMate 3 implantation, results show expected and acceptable survival, enhanced haemocompatibility, improved patient functional status and quality of life. This corroborates the success of HeartMate 3 since its first-in-man implantation case in Germany. ClinicalTrials.gov: NCT02170363.

Identifiants

pubmed: 30052304
doi: 10.1002/ejhf.1284
doi:

Banques de données

ClinicalTrials.gov
['NCT02170363']

Types de publication

Journal Article Multicenter Study Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

90-97

Commentaires et corrections

Type : CommentIn
Type : CommentIn

Informations de copyright

© 2018 The Authors. European Journal of Heart Failure © 2018 European Society of Cardiology.

Auteurs

Jan D Schmitto (JD)

Hannover Medical School, Hannover, Germany.

Yuriy Pya (Y)

National Research Cardiac Surgery Center, Astana, Kazakhstan.

Daniel Zimpfer (D)

University of Vienna, Vienna, Austria.

Thomas Krabatsch (T)

German Heart Center, Berlin, Germany.

Jens Garbade (J)

Heart Center Leipzig, Leipzig, Germany.

Vivek Rao (V)

Peter Munk Cardiac Centre, Toronto General Hospital, Toronto, Canada.

Michiel Morshuis (M)

Thoracic and Cardiovascular Surgery Clinic, Bad Oeynhausen, Germany.

Friedhelm Beyersdorf (F)

University Heart Center Freiburg-Bad Krozingen, Medical Faculty, Albert Ludwigs-University, Freiburg, Germany.

Silvana Marasco (S)

The Alfred Hospital, Melbourne, Australia.

Poornima Sood (P)

Abbott, Burlington, MA, USA.

Laura Damme (L)

Abbott, Burlington, MA, USA.

Ivan Netuka (I)

Institute for Clinical and Experimental Medicine, Prague, Czech Republic.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH